BiomX Inc.
Index- P/E- EPS (ttm)-1.39 Insider Own27.00% Shs Outstand29.75M Perf Week1.27%
Market Cap24.41M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float24.04M Perf Month-49.68%
Income-36.20M PEG- EPS next Q- Inst Own22.30% Short Float0.09% Perf Quarter-51.80%
Sales- P/S- EPS this Y-6.80% Inst Trans0.86% Short Ratio1.09 Perf Half Y-59.79%
Book/sh1.34 P/B0.60 EPS next Y- ROA-49.60% Target Price8.50 Perf Year-87.07%
Cash/sh1.80 P/C0.45 EPS next 5Y- ROE-75.90% 52W Range0.64 - 6.73 Perf YTD-49.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.11% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low25.02% ATR0.11
Employees103 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)23.70 Volatility10.34% 10.24%
OptionableNo Debt/Eq0.36 EPS Q/Q21.80% Profit Margin- Rel Volume5.78 Prev Close0.79
ShortableYes LT Debt/Eq0.35 EarningsMay 11 BMO Payout- Avg Volume20.43K Price0.80
Recom- SMA20-29.73% SMA50-42.71% SMA200-61.74% Volume108,661 Change1.28%
Apr-15-21Initiated Ladenburg Thalmann Buy $25
May-24-22 01:52AM  
May-20-22 08:00AM  
May-11-22 06:30AM  
May-06-22 07:00AM  
May-05-22 08:00AM  
Mar-30-22 06:30AM  
Mar-23-22 08:00AM  
Feb-24-22 08:00AM  
Jan-04-22 07:00AM  
Nov-17-21 08:00AM  
Nov-15-21 06:00AM  
Nov-09-21 08:00AM  
Oct-25-21 10:00AM  
Oct-18-21 07:00AM  
Oct-13-21 07:00AM  
Sep-02-21 04:05PM  
Aug-16-21 06:30AM  
Aug-12-21 08:00AM  
Jul-26-21 08:13AM  
Jun-14-21 06:30AM  
Jun-09-21 06:30AM  
May-25-21 10:46AM  
May-24-21 06:30AM  
May-18-21 08:00AM  
Apr-20-21 07:00AM  
Mar-31-21 06:30AM  
Mar-24-21 06:30AM  
Mar-02-21 07:00AM  
Mar-01-21 07:00AM  
Feb-02-21 06:30AM  
Jan-04-21 06:30AM  
Dec-09-20 04:30PM  
Dec-02-20 06:21PM  
Nov-16-20 06:30AM  
Nov-12-20 06:30AM  
Nov-10-20 04:30PM  
Nov-05-20 06:30AM  
Nov-04-20 06:30AM  
Oct-21-20 06:30AM  
Oct-05-20 06:30AM  
Sep-10-20 04:30PM  
Sep-02-20 06:30AM  
Aug-13-20 06:30AM  
Aug-12-20 12:17PM  
Aug-06-20 07:00AM  
May-14-20 06:30AM  
May-11-20 05:00PM  
Apr-07-20 04:05PM  
Mar-31-20 06:30AM  
Mar-26-20 06:30AM  
Mar-20-20 08:00AM  
Feb-17-20 07:00AM  
Dec-02-19 07:30AM  
Nov-12-19 07:30AM  
Nov-04-19 05:38PM  
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolfson MarinaSVP of Finance & OperationsJul 28Buy4.003,75015,0003,750Jul 30 09:55 AM
Sullivan Lynne MarieDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:53 AM
Solomon Jonathan EitanChief Executive OfficerJul 28Buy4.0025,000100,00025,000Jul 30 09:52 AM
Greig RussellDirectorJul 28Buy4.003,75015,0003,750Jul 30 09:50 AM
SEKHRI PAUL JDirectorJul 28Buy4.0012,50050,00012,500Jul 30 09:49 AM
Moses Alan CharlesDirectorJul 28Buy4.005,00020,0005,000Jul 30 09:48 AM